Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses
Nicolas Çuburu, … , Douglas R. Lowy, John T. Schiller
Nicolas Çuburu, … , Douglas R. Lowy, John T. Schiller
Published November 12, 2012
Citation Information: J Clin Invest. 2012;122(12):4606-4620. https://doi.org/10.1172/JCI63287.
View: Text | PDF
Research Article Immunology

Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses

  • Text
  • PDF
Abstract

The induction of persistent intraepithelial CD8+ T cell responses may be key to the development of vaccines against mucosally transmitted pathogens, particularly for sexually transmitted diseases. Here we investigated CD8+ T cell responses in the female mouse cervicovaginal mucosa after intravaginal immunization with human papillomavirus vectors (HPV pseudoviruses) that transiently expressed a model antigen, respiratory syncytial virus (RSV) M/M2, in cervicovaginal keratinocytes. An HPV intravaginal prime/boost with different HPV serotypes induced 10-fold more cervicovaginal antigen-specific CD8+ T cells than priming alone. Antigen-specific T cell numbers decreased only 2-fold after 6 months. Most genital antigen-specific CD8+ T cells were intra- or subepithelial, expressed αE-integrin CD103, produced IFN-γ and TNF-α, and displayed in vivo cytotoxicity. Using a sphingosine-1-phosphate analog (FTY720), we found that the primed CD8+ T cells proliferated in the cervicovaginal mucosa upon HPV intravaginal boost. Intravaginal HPV prime/boost reduced cervicovaginal viral titers 1,000-fold after intravaginal challenge with vaccinia virus expressing the CD8 epitope M2. In contrast, intramuscular prime/boost with an adenovirus type 5 vector induced a higher level of systemic CD8+ T cells but failed to induce intraepithelial CD103+CD8+ T cells or protect against recombinant vaccinia vaginal challenge. Thus, HPV vectors are attractive gene-delivery platforms for inducing durable intraepithelial cervicovaginal CD8+ T cell responses by promoting local proliferation and retention of primed antigen-specific CD8+ T cells.

Authors

Nicolas Çuburu, Barney S. Graham, Christopher B. Buck, Rhonda C. Kines, Yuk-Ying S. Pang, Patricia M. Day, Douglas R. Lowy, John T. Schiller

×

Figure 5

HPV PsV Ivag prime/boost immunization induces durable CD8+ T cell responses with an effector memory phenotype after HPV PsV Ivag immunization.

Options: View larger image (or click on image) Download as PowerPoint
HPV PsV Ivag prime/boost immunization induces durable CD8+ T cell respon...
Depo-Provera–treated mice were immunized with 5 × 107 IU HPV16MM2 or HPV16 control Ivag, and 1 month later mice were immunized with 5 × 107 IU HPV45MM2 or HPV45 control, respectively. (A) Cervicovaginal and blood cell suspensions were obtained from week 1 to week 14 and analyzed by flow cytometry for the presence of KdM282-tetramer+CD8+ T lymphocytes in HPVMM2 (squares) and HPV control (circles). Data are expressed as the mean percentage of KdM282-tetramer+CD8+ T lymphocytes in total CD8+ T lymphocytes + SD. (B) Representative plots of CD62L and CD127 expression of KdM282-tetramer+CD8+ T lymphocytes in cervicovaginal and blood cells suspensions collected at weeks 2, 7, and 14. The percentage of CD8+ T cells in each quadrant is indicated in each plot. Data are representative of 3 experiments.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts